RhumbLine Advisers
BBIO icon

RhumbLine Advisers’s BridgeBio Pharma BBIO Stock Holding History

RhumbLine Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Sell
171,188
-34,597
-17% -$2.42M 0.01% 982
2026
Q1 		$15.3M Sell
205,785
-7,686
-4% -$557K 0.01% 852
2025
Q4 		$16.3M Sell
213,471
-28,052
-12% -$1.84M 0.01% 821
2025
Q3 		$12.5M Sell
241,523
-6,213
-3% -$303K 0.01% 976
2025
Q2 		$10.7M Buy
247,736
+27,608
+13% +$1M 0.01% 1028
2025
Q1 		$7.61M Buy
220,128
+1,008
+0.5% +$34K 0.01% 1141
2024
Q4 		$6.01M Buy
219,120
+5,007
+2% +$129K 0.01% 1333
2024
Q3 		$5.45M Sell
214,113
-7,290
-3% -$191K ﹤0.01% 1387
2024
Q2 		$5.61M Buy
221,403
+36,199
+20% +$990K 0.01% 1333
2024
Q1 		$5.73M Buy
185,204
+4,374
+2% +$149K 0.01% 1345
2023
Q4 		$7.3M Buy
180,830
+1,071
+0.6% +$32.2K 0.01% 1213
2023
Q3 		$4.74M Buy
179,759
+1,924
+1% +$54.6K 0.01% 1379
2023
Q2 		$3.06M Buy
177,835
+15,448
+10% +$232K ﹤0.01% 1669
2023
Q1 		$2.69M Buy
162,387
+4,448
+3% +$51.9K ﹤0.01% 1656
2022
Q4 		$1.2M Buy
157,939
+5,635
+4% +$54K ﹤0.01% 2037
2022
Q3 		$1.51M Buy
152,304
+11,293
+8% +$117K ﹤0.01% 1924
2022
Q2 		$1.28M Buy
141,011
+17,520
+14% +$147K ﹤0.01% 2019
2022
Q1 		$1.25M Sell
123,491
-3,841
-3% -$39.4K ﹤0.01% 2038
2021
Q4 		$2.12M Sell
127,332
-899
-0.7% -$38K ﹤0.01% 1845
2021
Q3 		$6.01M Buy
128,231
+1,755
+1% +$94.1K 0.01% 1248
2021
Q2 		$7.71M Buy
126,476
+22,957
+22% +$1.31M 0.01% 1168
2021
Q1 		$6.38M Buy
103,519
+11,525
+13% +$754K 0.01% 1267
2020
Q4 		$6.54M Buy
91,994
+577
+0.6% +$27.8K 0.01% 1197
2020
Q3 		$3.43M Sell
91,417
-21,815
-19% -$686K 0.01% 1387
2020
Q2 		$3.69M Buy
113,232
+7,986
+8% +$243K 0.01% 1382
2020
Q1 		$3.05M Buy
105,246
+77,018
+273% +$2.39M 0.01% 1314
2019
Q4 		$989K Buy
28,228
+3,696
+15% +$102K ﹤0.01% 2091
2019
Q3 		$527K Buy
+24,532
New +$679K ﹤0.01% 2297

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

RhumbLine Advisers's BBIO Position: Q2 2026 in Review

RhumbLine Advisers reduced its BridgeBio Pharma (BBIO) stake by 17% in Q2 2026, selling an estimated $2.42M and leaving 171,188 shares worth $12.8M. The position accounts for 0.01% of the portfolio, ranked #982.

RhumbLine Advisers first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $16.3M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • RhumbLine Advisers held 171,188 shares of BridgeBio Pharma worth $12.8M as of Q2 2026.
  • RhumbLine Advisers sold 34,597 BridgeBio Pharma shares in Q2 2026, an estimated $2.42M.
  • BridgeBio Pharma made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #982 holding.
  • RhumbLine Advisers first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • RhumbLine Advisers's BridgeBio Pharma position peaked at $16.3M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.